The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.

PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.

A compound of Formula I, ##STR00001##
and its analogs are provided. Compositions that include Formula I can be used to inhibit human equilibrative nucleoside transporter 1, increase adenosine signaling and produce effects that include increasing antiviral activity, increasing antiparasitic activity, increasing alcohol tolerance, decreasing pain protecting from ischemia as well as many other conditions.

This invention provides selenium-based methods for treating refractory anemia with ring sideroblasts (RARS), cancer characterized by one or more genetic mutations associated with ring sideroblasts, and porphyria. This invention also provides related prophylactic methods, and articles of manufacture.

This invention provides selenium-based methods for treating refractory anemia with ring sideroblasts (RARS), cancer characterized by one or more genetic mutations associated with ring sideroblasts, and porphyria. This invention also provides related prophylactic methods, and articles of manufacture.

Provided are methods for reducing substance consumption by subjects. In some embodiments, the presently disclosed methods include administering to a subject in need thereof a composition that includes an effective amount of an inhibitor of an EHMT2/G9A biological activity. In some embodiments, the inhibitor of an EHMT2/G9A biological activity is a small molecule inhibitor, a nucleic acid-based inhibitor, and anti-EHMT2/G9A antibody or a fragment or derivative thereof, or any combination thereof. Also provided are methods for reducing relapse vulnerability in subjects that have Alcohol Use Disorder (AUD) and/or another substance use disorder. In some embodiments, the presently disclosed methods further include administering at least one additional therapy to subjects, including but not limited to behavioral therapies such as cognitive behavioral therapies.

Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.